- Home
- RBOT vs ATNM Comparison
RBOT vs ATNM Comparison
Compare RBOT & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBOT
- ATNM
- Stock Information
- Founded
- RBOT 2014
- ATNM 2000
- Country
- RBOT United States
- ATNM United States
- Employees
- RBOT N/A
- ATNM N/A
- Industry
- RBOT Medical Specialities
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- RBOT Health Care
- ATNM Health Care
- Exchange
- RBOT Nasdaq
- ATNM Nasdaq
- Market Cap
- RBOT 46.7M
- ATNM 51.5M
- IPO Year
- RBOT N/A
- ATNM N/A
- Fundamental
- Price
- RBOT $7.93
- ATNM $1.56
- Analyst Decision
- RBOT Hold
- ATNM Strong Buy
- Analyst Count
- RBOT 2
- ATNM 3
- Target Price
- RBOT $9.25
- ATNM $4.67
- AVG Volume (30 Days)
- RBOT 10.7K
- ATNM 508.8K
- Earning Date
- RBOT 08-11-2025
- ATNM 08-04-2025
- Dividend Yield
- RBOT N/A
- ATNM N/A
- EPS Growth
- RBOT N/A
- ATNM N/A
- EPS
- RBOT N/A
- ATNM N/A
- Revenue
- RBOT N/A
- ATNM N/A
- Revenue This Year
- RBOT N/A
- ATNM N/A
- Revenue Next Year
- RBOT N/A
- ATNM N/A
- P/E Ratio
- RBOT N/A
- ATNM N/A
- Revenue Growth
- RBOT N/A
- ATNM N/A
- 52 Week Low
- RBOT $4.27
- ATNM $1.03
- 52 Week High
- RBOT $19.00
- ATNM $8.64
- Technical
- Relative Strength Index (RSI)
- RBOT 50.26
- ATNM 48.47
- Support Level
- RBOT $7.21
- ATNM $1.41
- Resistance Level
- RBOT $8.09
- ATNM $1.49
- Average True Range (ATR)
- RBOT 0.45
- ATNM 0.11
- MACD
- RBOT -0.02
- ATNM -0.01
- Stochastic Oscillator
- RBOT 53.10
- ATNM 40.28
About RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.